Business
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers
About this update from Aclarion, Inc.
[{"type":"text","content":"Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain George Frey, MD Becomes Aclarion’s First KOL Surgeon to Onboard a Hospital MRI to add Nociscan Data to his Treatment Decisioning Process for Chronic Low Back Pain Patients Published Clinical Data Demonstrates That Patient Outcomes are Improved and Costs are Reduced When Surgical Treatment is Consistent With the Disc Levels Nociscan Identifies as Painful BROOMFIELD, CO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their expanded footprint in Colorado with AdventHealth Porter. From their location in Denver, AdventHealth Porter provides exceptional medical care to patients throughout the front range of Colorado. George Frey MD, Orthopedic Surgeon and founder of the Colorado Comprehensive Spine Institute said, “Treating patients effectively starts with an informed understanding of where their pain is coming from. In my experience with Nociscan, objectively measuring the biomarker content corelated with pain within a disc that may look healthy on an MRI, adds to my knowledge of how to treat that patient. At AdventHealth Porter, we are committed to provide the highest quality cost effective care possible. The published evidence is clear to me that adding Nociscan to our diagnostic evaluation may help us do that.” Brent Ness, CEO of Aclarion, said, “In keeping with our strategy to drive Nociscan to standard of care through KOL advocacy, we applaud AdventHealth Porter in bringing Nociscan technology to Denver in support of Dr. Frey’s vision to utilize our technology to improve outcomes while lowering costs. The support of pioneering leaders like Dr. Frey and AdventHealth is exactly the leadership we need to unequivocally demonstrate the superior clinical outcomes for patients that will drive coverage decisions by payers and give all patients access to Nociscan technology. We thank Dr. Frey and AdventHealth and look forward to the positive impact increasing Nociscan volumes will have on...